Protalix BioTherapeutics, Inc. (PLX)
NYSE American · Healthcare · Biotechnology
$2.710.00%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $218M
- P/E (trailing)
- 11.8
- Forward P/E
- 4.4
- 52-week range
- $1.60 – $3.19
- 52-week change
- +8.40%
- EPS (trailing)
- $0.23
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $52.7M (−1.23%)
- Net income
- −$6.6M
- Operating margin
- −10.4%
- Diluted EPS
- −$0.08
- Free cash flow
- −$13.6M
From the company’s annual report on SEC EDGAR.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Headquarters: Hackensack, United States · 226 employees · protalix.com